

## Low frequency of CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> T regulatory cells in Egyptian patients with chronic spontaneous urticaria

Mohamed A Elshayeb<sup>1</sup>, Mohamed N Farres<sup>1</sup>,  
Nermine AE Melek<sup>1</sup>, Asmaa S Mostafa<sup>1</sup>, Salah S  
Galal<sup>1</sup>, Nesrine A Mohamed<sup>2</sup>, Eman E Ahmed<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, Allergy & Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

<sup>2</sup>Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

**Corresponding author:** Eman E Ahmed, Department of Internal Medicine, Allergy & Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.  
Email: [dr.eman\\_khalil@med.asu.edu.eg](mailto:dr.eman_khalil@med.asu.edu.eg).

### Abstract

Chronic urticaria is a prevalent disabling dermatological disease. About 90%, are considered idiopathic and referred to as chronic spontaneous urticaria (CSU), and nearly half of them are likely to have autoimmune mechanisms. Regulatory T cells play a substantial role to prevent autoimmune diseases. Subsets of Tregs expressing the CD4<sup>+</sup>CD25<sup>high</sup> and forkhead-box-P3 (FOXP3) transcription factor, crucial for their development and function, are best characterized in maintenance of self-tolerance. The objective of this study was the analysis of peripheral CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (T regs) frequency in chronic spontaneous urticaria; and its possible association with autologous serum skin test (ASST). Fifty chronic spontaneous urticaria patients (25 with positive ASST and 25 with negative ASST) and 20 healthy controls were enrolled in this study. The frequency of CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (T regs) was analyzed by flow cytometry. A Significant decrease in peripheral blood CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> T regs% was detected in CSU patients in comparison to healthy individuals (median [IQR], 1.47% [0.71–3.12] vs 1.79% [1.15–4.00];  $P = 0.05$ ). When ASST positive patients were compared with ASST negative patients, no significant difference was found in percentage of T regs, ( $P=0.112$ ). In conclusion our data provided further insights into CSU pathogenesis. Reduced frequency of CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (Tregs) in patients with urticaria, support the notion that CSU is an immune mediated disease and may help researchers to develop a novel immunotherapy strategy.

**Keywords:** Regulatory T cells: T regs, CD25, Forkhead-box-P3: FOXP3, chronic spontaneous urticaria: CSU, Autologous Serum Skin Test: ASST.

**Date received:** 23 March 2021; **accepted:** 22 July 2021

### Introduction

Chronic urticaria (CU) is one of the common diseases that impacts, in a negative way, the general well-being of individuals affected.<sup>1</sup> It is characterized by the occurrence of wheals

spontaneously, mostly in middle age females, and continues for at least six weeks.<sup>2</sup> Most patients with CU remain undefined to a certain etiology and are classified as chronic idiopathic, in other words, spontaneous urticaria (CSU).<sup>3</sup> It

was found that chronic urticaria due to autoimmune causes was demonstrated in around 30-50% of CSU cases and are referred to as chronic autoimmune urticaria (CAU).<sup>4</sup> This autoimmunity is caused by a disorder in self-tolerance, which is normally preserved due to immune balance.<sup>5,6</sup>

One of the important components that is crucial in maintaining this balance is the regulatory T cells (Tregs).<sup>7</sup> The most widely identified T regulatory cell is a CD4<sup>+</sup> subpopulation expressing high levels of CD25 and the transcription factor FOXP3.<sup>8,9</sup> This CD4<sup>+</sup>CD25<sup>high</sup> FOXP3<sup>+</sup>Treg counteract the action of auto-aggressive T cells, therefore saving the body from autoimmune diseases.<sup>10,11</sup>

Any disorder in the expression of FOXP3 leads to devastating consequences ending in autoimmune diseases and even allergy.<sup>12-14</sup> Therefore, FOXP3 is the cornerstone element mandatory for proper development and function of CD4<sup>+</sup>CD25<sup>+</sup> T cell.<sup>5</sup> Moreover, FOXP3 expression is specific for Treg and thereby allows easy and accurate quantification and detection of Treg.<sup>15</sup>

Autologous Serum Skin Test (ASST) is regarded as a test for autoreactivity rather than a specific test for autoimmune urticaria. CU patients with a positive ASST are more likely to be associated with HLADR4, to have autoimmune thyroid disease, a more prolonged disease course and may be less responsive to antihistamine treatment than those with a negative ASST.<sup>16</sup>

For a better understanding of CSU pathology, the aim of the present study was to measure the frequency of circulating CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup>(Tregs) in patients with chronic spontaneous urticaria (CSU), compared to healthy controls, and its possible association with ASST.

## Subjects and Methods

### Study participants

This cross-sectional case-control study included 70 participants, among whom 50 were patients with chronic spontaneous urticaria (7 males and 43 females; median age; 34.9 ± 11.8 years) and 20 were healthy controls (10 males and 10

females; median age 36.6 ± 11.6 years). The patients were recruited from the Allergy and Clinical Immunology clinic at Ain Shams University Hospitals. Inclusion criteria were patients complaining of spontaneous appearance of wheals, angioedema or both for > 6 weeks. They were diagnosed according to the EAACI/GA2LEN/EDF/WAO evidence and consensus-based guideline.<sup>17</sup> Patients with acute, allergic, physical or vasculitic urticaria, were excluded. None of them was pregnant, lactating or having major systemic illnesses. Antihistamines were stopped a week before enrollment, and systemic corticosteroid or immunosuppressive for at least 12 weeks, patients who suffered significant exacerbations or couldn't withstand stopping treatment were excluded from participation and received their treatment back. The control subjects were apparently healthy with negative history of allergy, urticaria or any other disease, besides they were age-matched and of the same social class as far as possible. An informed written consent was obtained from all participants. The study was approved by the institutional ethical committee board of Ain Shams University.

### Study design

Assessment of participants included medical history, full clinical examination, and routine blood tests such as CBC, ESR, liver and renal function tests. Antithyroid antibodies, serum total IgE, autologous serum skin test (ASST) and CD4<sup>+</sup>CD25<sup>high</sup> FOXP3<sup>+</sup>Treg cell assay were measured for all patients. Based upon ASST results, the 50 CSU patients were categorized into 2 groups 25 patients with positive ASST and 25 patients with negative ASST.

### Laboratory tests

-From each participant, 6 ml of venous blood were taken, where 3 ml were placed in an EDTA vacutainer tube (Becton Dickinson, Oxford, UK) for performing complete blood count (CBC) and CD4<sup>+</sup>CD25<sup>high</sup> FOXP3<sup>+</sup>Treg cells estimation by flow cytometry. The remaining of the blood was collected into a gel vacutainer tube (Becton Dickinson), and left to coagulate for half an hour. Serum was obtained by centrifugation at 1000 x g for quarter an hour and divided into

two aliquots; one aliquot for routine lab immediate assay Parameters (AST, ALT, creatinine, and BUN), while the remaining part of sera was aliquoted and stored at  $-20^{\circ}\text{C}$  until used for the anti-thyroid antibodies, thyroid-stimulating hormone (TSH) and total serum immunoglobulin E (IgE) levels. All tests were performed at the Department of Clinical Pathology- Ain Shams University.

-CBC was done utilizing "Coulter counter" (T660) (Beckman. Coulter, California, USA).

-AST, ALT, creatinine, and BUN were measured on Synchron CX-9 autoanalyzer (Beckman Instruments Inc.; Scientific Instruments Division, Fullerton, CA, USA).

-Anti-thyroid antibodies (anti-thyroperoxidase and anti-microsomal antibodies) were performed by indirect immunofluorescence assay using commercially available kits (Inova Diagnostics, USA), according to the manufacturer's instructions.

-Total serum IgE levels (IU/ml) was estimated using an enzyme linked immunosorbent assay (ELISA) kit supplied by Biopharm (RIDASCREEN; R-Biopharm, Darmstadt, Germany) according to the manufacturer's instructions. This procedure has a sensitivity of 1IU/ml. The normal level of total IgE, in adults, is less than 100 IU/ml.

#### *CD4<sup>+</sup>CD25<sup>high</sup> FOXP3<sup>+</sup>Treg flowcytometry analysis*<sup>18,19</sup>

The test was done on lysed whole blood using three colors EPICS XL flow cytometer (Coulter Electronics, Florida, USA), by using the following monoclonal antibodies conjugated with different fluorescent dyes: Fluorescein isothiocyanate (FITC)-conjugated anti-human CD4, Phycoerythrin (PE)-conjugated anti-human CD25, Phycoerythrin-Cyanine 5 (PE-Cy5)-conjugated anti-human FOXP3, PE-Cy5 isotype control, and PE isotype control, supplied by (eBioscience, USA). Two plastic test tubes were used: one for the test and the other for the isotypic control. According to the manufacturer's protocol, 50 $\mu\text{L}$  of EDTA treated


whole blood were added to each tube, which contained 1 mL lysing solution, followed by a wash with phosphate-buffered saline (PBS). Then the cell pellet was stained with combinations of the following monoclonal antibodies (5  $\mu\text{L}$  each): anti-CD4-FITC, anti-CD25-PE in the test tube; PE isotype control and anti-CD4-FITC in the control tube. Both tubes were then incubated at room temperature protected from light for 20 minutes, then washed once with PBS.

#### *-Intracellular FOXP3 staining:*

The cell pellet was re-suspended in 0.5 ml of freshly prepared fixation/permeabilization working solution and incubated for 30 minutes in the dark at  $4^{\circ}\text{C}$ . This was followed by washing once with PBS, then washing once again with 1 ml of 1x permeabilization buffer. Ten  $\mu\text{L}$  of anti-FOXP3-PE-Cy5 monoclonal and PE-Cy5 isotype control were added in the test tube and control tube, respectively, and incubated for 30 minutes at  $4^{\circ}\text{C}$  with minimal exposure to light. This was followed by washing once with PBS, then the stained cell pellet is re-suspended in 0.5 mL PBS sheath fluid solution for analysis by flow cytometer.

-Data acquisition and analysis were performed by EPICS XL flowcytometry, using SYSTEM II version 3 software with a standard three-color filter configuration. Isotype-matched controls were used to set up the threshold for gating.

-Lymphocytes were firstly identified according their size and complexity on the forward/side scatter plot (figure 1-A). CD4<sup>+</sup>T cells were identified based on CD4<sup>+</sup> expression (figure 1-B). PE isotype control was used to set gates separating CD4<sup>+</sup>CD25<sup>+</sup> cells from CD4<sup>+</sup>CD25<sup>-</sup> cells. Then according to the intensity of positive expression of CD25 on CD4<sup>+</sup> cells, two areas on the plot were noticed: the dim area (CD4<sup>+</sup>CD25<sup>low</sup>) (figure 1-D region F), and the bright one (CD4<sup>+</sup>CD25<sup>high</sup>) (figure 1-D region E). PE-Cy5 isotype control was used to set the gates for separating FOXP3<sup>+</sup> cells from FOXP3<sup>-</sup> cells. Tregs were identified by the combined expression of CD4<sup>+</sup>, CD25<sup>high</sup> and FOXP3.



**Figure 1.** Gating strategy of the flowcytometric analysis of CD4<sup>+</sup>CD25<sup>high</sup> cells in peripheral blood. Representative dot plots of flow cytometry and the gating strategy used (A to D). (A) Shows forward and side scatter to gate lymphocytes. (B) Shows that CD4<sup>+</sup> cells were acquired after gating the lymphocyte population by forward and side scatter properties. (C) and (D) show the gating approach for CD25<sup>+</sup> cells and for discrimination between CD25<sup>high</sup> (figure 1-D region E) and CD25<sup>low</sup> (figure 1-D region F) on CD4<sup>+</sup> cells. The gates for the CD25<sup>high</sup> and CD25<sup>low</sup> populations were set by comparing the CD25 expression levels of CD4<sup>+</sup> cells.

#### Autologous serum skin test (ASST)

ASST was performed according to the recommended methodology of an expert panel, representing the Dermatology section of the European Academy of Allergy and Clinical Immunology (EAACI).<sup>20</sup> Patients were instructed to stop Antihistamines a week before enrollment, and systemic corticosteroid or immunosuppressive for at least 12 weeks as mentioned above. Venous blood was collected into sterile glass tubes without accelerator or anticoagulant. Blood was allowed to clot at room temperature for 30 min before separation. Separation was done with a bench centrifugation of 450–500 x g for 10 minutes. The volar forearm skin was cleaned with antiseptic, avoiding the wrist and skin areas known to have had spontaneous wheals in the previous 48 h.

The ASST was performed with a 0.5–1 ml sterile syringe and needle 27G. 0.05 ml of fresh undiluted serum was injected intradermally in by introducing the bevel of the needle uppermost and aiming to raise a palpable bleb of fluid within the papillary dermis. The ASST response was validated by performing a positive histamine control, by intradermal injection of 0.5–1 µg histamine (50 µl of 10–20 µg/ml histamine solution). As a negative control skin test, 50 µl sterile physiological (normal) saline was injected intradermally using the same method as for serum, leaving 3–5 cm gaps between each of the three injections. After half an hour, a clean transparent ruler was pressed lightly onto the skin surface of a positive ASST to demonstrate the oedema within a skin test site more easily by blanching the erythema. ASST is positive if ASST mean wheal is about 1.5 mm in diameter, or more than the response induced by saline.

#### Statistical analysis

We analyzed our data using IBM® SPSS® Statistics version 24 (IBM® Corp., Armonk, NY) and MedCalc® version 14 (MedCalc® Software bvba, Ostend, Belgium). To examine the normality of numerical data distribution we applied Shapiro-Wilk test. Then we presented normally distributed numerical variables as mean ± SD and used unpaired t-test to compare inter-group differences. Median and interquartile represent non-normally distributed numerical data and Mann-Whitney test was applied to compare intergroup differences. Categorical variables were presented as ratio or number and percentage and we used Fisher's exact test to compare differences. *P*-values ≤ 0.05 were considered statistically significant.

#### Results

A total of 50 cases and 20 healthy controls were included in the study. Both groups were comparable for age and sex. Demographic and clinical characteristics of CSU group are shown in table 1.


**Table 1.** Demographic and clinical characteristics of CSU patients.

Variable	Cases (n=50)
Age (years): mean±SD	34.9 ±11.8
Gender(M/F)	7/43
Disease duration (years)	2 (0.67 - 6)
Family history of atopy: n (%)	
Negative	43 (86.0%)
Positive	7 (14.0%)
Frequency of attacks: n(%)	
Daily	33 (66.0%)
Every other day	8 (16.0%)
Weekly	6 (12.0%)
Monthly or Occasionally	3 (6.0%)
Associated Angioedema	28 (56.0%)
Positive antithyroid antibodies	11 (22.0%)

#### Frequency of $CD4^+CD25^{high}FOXP3^+$ (Tregs)

As regards the frequency of  $CD4^+CD25^{high}FOXP3^+$  (Tregs) in both cases and controls, the percentages of these cells were significantly reduced in CSU patients [1.47 (0.71 - 3.12) %] compared to healthy controls [1.79 (1.15 - 4.00) %] ( $P=0.05$ ) (figure 2).

No significant correlation was detected between both T-cell subpopulation and age of the cases or disease duration (data not shown).




**Figure 2.** Box plot showing the  $CD4^+CD25^{high}FOXP3^+$  (Tregs) % in peripheral blood of patients with CSU and controls. The T reg cells were significantly lower in patients with CSU than controls.

#### Frequency of $CD4^+CD25^{high}FOXP3^+$ (Tregs) in patients; classified based on the results of antithyroid antibody tests

$CD4^+CD25^{high}FOXP3^+$  (Tregs) % was lower in CSU patients with positive antithyroid antibodies (n=11), compared to those with negative antithyroid antibodies (n=39); 0.95 (0.56 - 1.75) vs 1.55 (0.78 - 3.17) % respectively. Still this difference did not reach statistical significance.

#### Frequency of $CD4^+CD25^{high}FOXP3^+$ (Tregs) in patients; classified based on the results of ASST

The CSU patients were selected as two groups; ASST positive and ASST negative groups. Although median and IQR of  $CD4^+CD25^{high}FOXP3^+$  (Tregs) % was lower in ASST positive group [0.95 % (0.64 - 2.46)] than in ASST negative group [1.58 (1.09 - 3.36)], yet this reduction did not reach statistical significance (Figure 3).



**Figure 3.** Comparison between CSU patients with positive ASST and negative ASST. As regards percentage of  $CD4^+CD25^{high}FOXP3^+$  Treg cells in peripheral blood showing lower percentage in cases with positive ASST.

## Discussion

Chronic urticaria is complex in pathogenesis and therefore it is not utterly understood.<sup>21</sup> Our aim mainly in this study was to determine if CSU is associated with altered peripheral Treg cell homeostasis. We investigated the proportion of  $CD4^+CD25^{high}FOXP3^+$  (Tregs) in the peripheral blood of CSU patients.

T regulatory cells (Tregs) have been recently discovered as a unique subpopulation of T cells, which crucially function on the prevention of



autoimmunity and regulate transplantation tolerance.<sup>24</sup> In humans, CD4<sup>+</sup>CD25<sup>+</sup> T cells are stratified into two populations; suppressive CD4<sup>+</sup>CD25<sup>high</sup> T cells and non-suppressive CD4<sup>+</sup>CD25<sup>low</sup> T cells.<sup>23</sup> A fundamental marker of regulatory T cells is FOXP3, which is a transcription factor essential for proper operation of CD4<sup>+</sup>CD25<sup>+</sup> Tregs.<sup>24</sup> The fraction of FOXP3<sup>+</sup> cells is present more within the CD25<sup>high</sup> compared with the total CD25<sup>+</sup> T cell subset.<sup>25</sup>

In this study, we first demonstrated that CSU patients compared to healthy controls showed statistically significant reduction in peripheral frequencies of CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup>(Tregs). On comparing ASST positive with ASST negative patients we found CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (Tregs) % more reduced in ASST positive group, although this reduction did not reach a statistical significance. Deficiency of regulatory T cells (Treg) in CSU further suggests a significant role played by these cells in suppressing autoimmune processes.

In support of this hypothesis, Sun et al.<sup>26</sup> previously published data, showed decreased frequency of CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup>cells in CU patients when compared to healthy control group. Additionally, there was lower expression of FOXP3 rather than number of cells in chronic autoimmune urticaria opposed to chronic idiopathic urticaria in general. This decreased expression of transcription factor FOXP3 in CD4<sup>+</sup>CD25<sup>high</sup>Treg cells could explain their altered function, and consequently justifies the occurrence of autoimmune phenomenon. The authors however owed reduced frequency of CD4<sup>+</sup>CD25<sup>high</sup> FOXP3<sup>+</sup>cells in CU patients to their preferable shift to the sites of active inflammation, thus leaving the circulation.<sup>26</sup> Opposite to this assumption, a decreased proportion of CD4<sup>+</sup>FOXP3<sup>+</sup>Tregs, was detected in the inflammatory infiltrate in skin of patients with cutaneous lupus erythematosus, and on the other hand no difference in the peripheral frequency of circulating CD25<sup>high</sup> and FOXP3<sup>+</sup>cells between the same patients and controls.<sup>27</sup> Interestingly, Antiga et al.<sup>28</sup> revealed a significantly reduced frequency of CD25<sup>high</sup>FOXP3<sup>+</sup>cells in peripheral blood of scleroderma and morphea patients when compared with healthy controls and

inflammatory dermatoses patients. Also, in the same patients, and when measured in cutaneous infiltrate, FOXP3 expression and FOXP3<sup>+</sup>/CD4<sup>+</sup> cell ratios were significantly reduced. These findings propose that diminished Tregs within the circulation of patients suffering from autoimmune pathology was not necessarily the result of their favorable homing into the skin, or the reverse, it rather denotes a real down regulation of these cells, which subsequently participate in the pathogenesis of autoimmune diseases. In addition, this highly raises the needs to study more deeply the kinetics of Tregs in these conditions.

Furthermore Arshi et al.<sup>29</sup> in agreement with our findings, reported a significantly lower percentage of circulating CD4<sup>+</sup>CD25<sup>+</sup> FOXP3<sup>+</sup> T cells in CU patients compared to control subjects, however after classifying their patients according to the response to ASST, there were no significant differences in the level of circulating Tregs between patients with ASST-positive and ASST-negative CU. This could might indicate an underlying immune dysregulation in CSU both ASST positive and ASST negative.

On the other hand, Chen et al.<sup>30</sup> surprisingly, found that patients with CU had more CD4<sup>+</sup>CD25<sup>high</sup>Treg cells in peripheral blood mononuclear cells than did healthy control subjects. No difference was identified between ASST positive and ASST negative patients, both showed significantly more numbers of CD4<sup>+</sup>CD25<sup>high</sup> T cells compared to control subjects, while FOXP3 expression in CD4<sup>+</sup>CD25<sup>+</sup>Treg cells from patients and controls, did not significantly differ. Somehow in line with this, Ou et al.<sup>31</sup> observed significantly higher CD4<sup>+</sup>CD25<sup>+</sup> T cells in atopic dermatitis patients. Chen et al.<sup>30</sup> data on the function of CD4<sup>+</sup>CD25<sup>+</sup> cells demonstrated that some patients with CU have disturbed regulatory activity, supporting the possible role of a deficient immunoregulatory function in the pathogenesis of CU. The increase in frequency of Treg cells reported in this study can be explained by being a compensatory mechanism for their defective function in CU patients or just expanded proportion of functionally deranged Tregs. The connection between CU and autoimmune

thyroid disease is unquestioned. About 25% of patients with CIU have antithyroid antibodies, regardless of thyroid functional status.<sup>32</sup> In the present study, we showed reduced both cell subtypes more in CSU patients with positive antithyroid antibodies (n=11), compared to those with negative antithyroid antibodies (n=39), although no statistically significant difference was obtained. In this regard Bossowski et al.<sup>33</sup> found out CD4<sup>+</sup>CD25<sup>high</sup> T lymphocytes and CD4<sup>+</sup>FOXP3<sup>+</sup> significantly decreased in patients with Graves' disease and Hashimoto thyroiditis (untreated), when compared to healthy control subjects, pointing to their role in triggering and may be the ongoing autoimmune process in thyroid diseases. Also, a report by Qin et al.<sup>34</sup> studying patients with new-onset Graves' Disease, observed a significantly decreased proportion of circulating CD4<sup>+</sup>FOXP3<sup>+</sup>Treg cells and reduced mRNA expression of the transcription factor FOXP3. They also found an inverse correlation between the proportion of CD4<sup>+</sup>FOXP3<sup>+</sup>Treg cells and thyroid-stimulating antibody activity, proposing that these deficient Treg cells in Graves' Disease patients likely lose their capacity to prevent B cells from producing autoantibodies.

Earlier studies<sup>35</sup> revealed that animal models lacking CD4<sup>+</sup>CD25<sup>+</sup>Tcells developed different autoimmune disease, including autoimmune gastritis, thyroiditis, and type 1 diabetes. Besides, it has been shown in transgenic mice, in which endogenous FOXP3 gene expression is reduced in Th cells, that decreased expression of FOXP3 caused immune disease by impairing the suppressive capacity of these cells and converting them into a type of cells that initiated, rather than inhibited, inflammation.<sup>36</sup> In human, several reports have shown a relationship between various autoimmune diseases and the deficiency of the number or function of Treg cells. In Systemic Lupus Erythematosus patients, Liu et al. and Crispin et al. detected a low number of CD4<sup>+</sup>CD25<sup>+</sup>Tregs,<sup>37,38</sup> while a reversible defect in the suppressive function of CD4<sup>+</sup>CD25<sup>+</sup>Tregs from active SLE patients was reported by Valencia et al.<sup>39</sup> Miyara et al.<sup>40</sup> however, demonstrated that the number rather than the

function of CD4<sup>+</sup>CD25<sup>+</sup>Treg in active SLE patients was reduced. These inconsistent results might be related to the therapeutic modalities given to SLE patients before being enrolled into the studies. Zhang et al.<sup>41</sup> studied new-onset SLE patients before receiving treatment, to rule out the effect of various medications, and found significantly decreased percentage of CD4<sup>+</sup>CD25<sup>+</sup> T cells and CD4<sup>+</sup>CD25<sup>high</sup> subpopulation within CD4<sup>+</sup> T cells in the new-onset active SLE patients when compared to inactive patients.

In active Vogt-Koyanagi-Harada syndrome (VKH) which is an autoimmune ocular disease, a significantly decreased percentage of CD4<sup>+</sup>CD25<sup>high</sup> Tregs and CD4<sup>+</sup>CD25<sup>high</sup> FOXP3<sup>+</sup> cells were observed, compared with healthy controls and patients with inactive VKH. This result suggested a definite correlation between decreased frequency of these cells and active autoimmune uveitis in VKH patients.<sup>42</sup>

"How much FOXP3 expressing natural Treg is reduced, will define the phenotype and severity of autoimmune disease based upon the hierarchical genetic predisposition of each autoimmune disease".<sup>43</sup> Recent evidence showed that CD4<sup>+</sup>CD25<sup>+</sup>Tregs may even cure certain autoimmune diseases, for example, inflammatory bowel disease in animal models.<sup>44</sup>

In conclusion, we provided evidence for a decreased frequency of CD4<sup>+</sup>CD25<sup>high</sup>FOXP3<sup>+</sup> (Tregs) % in CSU patients regardless of the other autoreactivity available investigations such as ASST or antithyroid antibodies. In the light of our own data and other different studies, deficiency of these cells could be a sign of immune dysregulation, that plays a role in the pathogenesis of CSU with potential for therapeutic manipulation to produce increases in Tregs numbers, noting such treatment remains speculative since another possibility is that reduced numbers of these cells may be a consequence, i.e., epiphenomenon, rather than a cause of CSU.

Limitation of the study was the relatively small sized sample. This may be explained by the strict selection of patients. Detection of other cytokines and correlation with Treg cells frequency would have been useful to determine the exact role in CSU.

## Author Contributions

MAE: Conceptualization, supervision, MNF: Methodology, statistical analysis. NAEM writing original draft. SSG and ASM: Data curation, SSG: Resources. NAM: Investigation. EEA: Writing, Reviewing and Editing.

## Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The authors deny receipt of any financial support for the research, authorship, and/or publication of this article

## Ethical approval

The study was approved by the institutional ethical committee board of Ain Shams University.

## Informed consent

A signed consent form was obtained from each study participant.

## References

1. Sabroe RA and Greaves MW (2009) "What is urticaria? Anatomical, physiological, and histologic consideration and classification," in Urticaria and Angioedema, A. P. Kaplan, Ed., pp. 1–14, Informa Health Care, New York, NY, USA, 2nd edition,
2. Goh CL and Tan KT (2009). Chronic autoimmune urticaria: Where we stand? Indian J Dermatol; 54: 269-74.
3. Zuberbier T (2013). Classification of urticaria. Indian J Dermatol; 58:208-10.
4. Godse KV (2004). Autologous serum skin test in chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol; 70:283-4.
5. Valencia X and Lipsky PE (2007). "CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells in autoimmune diseases. Nature Clinical Practice Rheumatology; 3(11):619–626.
6. Jain S (2014). Pathogenesis of chronic urticaria: an overview. Dermatol Res Pract; 2014: 674709.
7. Brusko TM, Putnam AL and Bluestone JA (2008). Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev; 223:371–390.
8. Hori S, Nomura T and Sakaguchi S (2003). Control of regulatory T-cell development by the transcription factor Foxp3. Science; 299(5609): 1057–1061.
9. Fontenot JD, Gavin MA and Rudensky AY (2003). Foxp3 programs the development and function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cells. Nat Immunol; 4(4):330–336.
10. Baecher-Allan C and Hafler DA (2006). Human regulatory T cells and their role in autoimmune disease. Immunol Rev; 212:203–16.
11. Sakaguchi S (2005). Naturally arising FOXP3-expressing CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells in immunological tolerance to self and non-self. Nat Immunol; 6:345–52.
12. Bennett C L, Christie J, Ramsdell F, et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet; 27: 20–21.
13. Barzaghi F, Passerini L and Bacchetta R (2012). Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol; 3: 211.
14. Sakaguchi S, Yamaguchi T, Nomura T, et al. (2008) Regulatory T cells and immune tolerance. Cell; 133:775–787.
15. Hori S, Nomura T and Sakaguchi S (2003). Control of regulatory T cell development by the transcription factor FOXP3. Science; 299:1057–61.
16. Kocatürk E, Kavala M, Kural E, et al. (2011) Autologous serum skin test vs autologous plasma skin test in patients with chronic urticaria: evaluation of reproducibility, sensitivity and specificity and relationship with disease activity, quality of life and anti-thyroid antibodies. Eur J Dermatol. 21(3):339-43.
17. Zuberbier T, Aberer W, Asero R, et al. (2014) European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 69(7):868-87.
18. Salwa IB, Manal ZM, Dina AS (2013). Role of Regulatory CD4<sup>+</sup>CD25<sup>+</sup> Foxp3 T Cells in Bronchial Asthma in Egyptian Children. Egypt J Immunol. 20 (2): 29-38
19. Ahlam MI, Sanaa SA, Hanan MF, et al. (2015) Serum 25-hydroxyvitamin D and CD4<sup>+</sup>CD25<sup>high</sup> FoxP3<sup>+</sup> Regulatory T cell as Predictors of Severity of Bronchial Asthma in Children. Egypt J Immunol. 22 (1): 9-18



20. Konstantinou GN, Asero R, Maurer M, et al. (2009) EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. *Allergy*. 64(9):1256-68.
21. Kaplan AP, and Greaves M (2009) Pathogenesis of chronic urticaria. *Clin Exp Allergy*. Jun; 39(6):777-87.
22. Bluestone JA and Abbas AK (2003) Natural versus adaptive regulatory T cells. *Nat Rev Immunol*; 3:253-7.
23. Baecher-Allan C, Brown JA, Freeman GJ, et al. (2001) CD4<sup>+</sup>CD25<sup>high</sup> regulatory cells in human peripheral blood. *J Immunol*; 167:1245-53.
24. Brunkow ME, Jeffery EW, Hjerrild KA, et al. (2001) Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *J Nat Genet*; 27:68-73.
25. Grindebacke H, Stenstad H, Quiding-Järbrink M, et al. (2009) Dynamic development of homing receptor expression and memory cell differentiation of infant CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells. *J Immunol*; Oct 1; 183(7):4360-70.
26. Sun RS, Sui JF, Chen XH, et al. (2011) Detection of CD4<sup>+</sup>CD25<sup>+</sup> FOXP3<sup>+</sup> regulatory T cells in peripheral blood of patients with chronic autoimmune urticaria. *Australas J Dermatol*; Aug; 52(3):e15-8.
27. Franz B, Fritzsche B, Riehl A, et al. (2007) Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. *Arthritis Rheum*; 56:1910-20.
28. Antiga E, Quaglini P, Bellandi S, et al. (2010) Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphea. *Br J Dermatol*; 162(5):1056-63.
29. Arshi S, Babaie D, Nabavi M, et al. (2014) Circulating level of CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> T cells in patients with chronic urticaria. *Int J Dermatol*; 53(12):e561-6.
30. Chen WC, Chiang BL, Liu HE, et al. (2008) Defective functions of circulating CD4<sup>+</sup>CD25<sup>+</sup> and CD4<sup>+</sup>CD25<sup>-</sup> T cells in patients with chronic ordinary urticaria. *J Dermatol Sci*; 51:121-30.
31. Ou LS, Goleva E, Hall C, et al. (2004) T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. *J Allergy Clin Immunol*; 113:756-63.
32. Kaplan AP (2004) Chronic urticaria: pathogenesis and treatment. *J Allergy Clin Immunol*. Sep; 114(3):465-74.
33. Bossowski A, Moniuszko M, Dąbrowska M, et al. (2013) Lower proportions of CD4<sup>+</sup>CD25<sup>(high)</sup> and CD4<sup>+</sup>FOXP3, but not CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>(low)</sup> FOXP3<sup>+</sup> T cell levels in children with autoimmune thyroid diseases. *Autoimmunity*; May; 46(3):222-30.
34. Qin J, Zhou J, Fan C, et al. (2017) Increased Circulating Th17 but Decreased CD4<sup>+</sup>FOXP3<sup>+</sup> Treg and CD19<sup>+</sup>CD1d<sup>hi</sup>CD5<sup>+</sup>Breg Subsets in New-Onset Graves' Disease. *Biomed Res Int*; 2017:8431838.
35. Sakaguchi S, Sakaguchi N, Asano M, et al. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol*; Aug 1; 155: 1151-1164.
36. Wan YY and Flavell RA (2007) Regulatory T-cell functions are subverted and converted owing to attenuated FOXP3 expression. *Nature*; 445: 766-70.
37. Liu MF, Wang CR, Fung LL, et al. (2004) Decreased CD4<sup>+</sup>CD25<sup>+</sup> T cells in peripheral blood of patients with systemic lupus erythematosus. *Scand J Immunol*; 59:198-202.
38. Crispin JC, Martinez A and Alcocer-Varela J (2003) Quantification of regulatory T cells in patients with systemic lupus erythematosus. *J Autoimmun*; 21:273-6.
39. Valencia X, Yarboro C, Illei G, et al. (2007) Deficient CD4<sup>+</sup>CD25<sup>high</sup> T regulatory cell function in patients with active systemic lupus erythematosus. *J Immunol*; 178:2579-88. <https://doi.org/10.4049/jimmunol.178.4.2579>
40. Miyara M, Amoura Z, Parizot C, et al. (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. *J Immunol*; 175:8392-400.
41. Zhang B, Zhang X, Tang F, et al. (2008) Reduction of forkhead box P3 levels in CD4<sup>+</sup>CD25<sup>high</sup> T cells in patients with new-onset systemic lupus erythematosus. *Clin Exp Immunol* Aug; 153(2):182-7.
42. Chen L, Yang P, Zhou H, et al. (2008) Diminished frequency and function of CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. *Invest Ophthalmol Vis Sci*; Aug; 49(8):3475-82.
43. Ono M, Shimizu J, Miyachi Y, et al. (2006) Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), FOXP3-expressing CD25<sup>+</sup> and CD25<sup>-</sup> regulatory T cells. *J Immunol*; Apr 15; 176(8):4748-56.
44. Uhlig HH, Coombes J, Mottet C, et al. (2006) Characterization of FOXP3<sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup> and IL-10-secreting CD4<sup>+</sup>CD25<sup>+</sup> T cells during cure of colitis. *J Immunol*; 177:5852-60.